We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Second Pathology Analysis Ensures Proper Diagnosis and Treatment

By LabMedica International staff writers
Posted on 27 May 2015
A pathologic diagnosis is the foundation upon which all other treatment decisions are made with breast cancer and with the emergence of target therapy, the pathology dictates the use of potentially curable therapy.

Patients with breast disease receive appropriate care based on accurate diagnoses and accurate identification of predictive and prognostic markers as an incorrect pathologic diagnosis may lead to negative outcomes as serious as failure to treat a missed case of breast cancer or provision of unnecessary surgery, chemotherapy, and radiation.

Pathologists at the Roswell Park Cancer Institute (Buffalo, NY, USA) reviewed 502 breast core biopsy cases provided by referring institutions in a single calendar year. More...
A core needle biopsy is a procedure that removes small samples of breast tissue which are then analyzed for characteristics of breast disease. The cases in the study were defined as reflecting a minor discordance when the change in diagnosis did not impact the patient and a major discordance when patient care was impacted through a change in therapy modality.

The team found that 8% of the cases had a major discordance and 13% had a minor discordance. The most common reason for major discordance is interpreting biomarkers such the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factors type 2 (HER-2). These biomarkers can determine treatment options and may predict breast cancer survival. The second most common reason was borderline diseases. The change of diagnosis from benign to malignant or vice versa, while less common, was identified in 1% of the cases examined. This change has the most significant impact on patient care and outcome.

The scientists did not find any difference in the rate of discordance between institutions or with regard to the pathologists' seniority. However, none of the providing pathologist was specialized in breast pathology which might explain the discordance. In conclusion, they recommend that second review of the original pathologic material should be evaluated by specialized pathologist prior to any therapeutic implementations. Thaer Khoury, MD, a coauthor of the study said, “Surgical pathology is a dynamically changing specialty with frequently updated guidelines and classifications. This study underscores the need for a second review of the original pathologic material by a pathologist who specializes in breast cancer prior to implementation of breast cancer therapy.” The study was published online on April 15, 2015, in the Breast Journal.

Related Links:

Roswell Park Cancer Institute



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.